UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000050602
Receipt number R000057506
Scientific Title Pharmacokinetic model for Remimazolam in patients undergoing cardiac surgery
Date of disclosure of the study information 2023/03/16
Last modified on 2024/03/15 10:27:52

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Pharmacokinetic model for Remimazolam in patients undergoing cardiac surgery

Acronym

Phamcokinetic model for Remimazolam

Scientific Title

Pharmacokinetic model for Remimazolam in patients undergoing cardiac surgery

Scientific Title:Acronym

Pharmacokinetic model for Remimazolam in patients undergoing cardiac surgery

Region

Japan


Condition

Condition

aortic valve disease

Classification by specialty

Cardiovascular surgery

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To establish PK model for remimazolam in patients undergoing cardiac surgery

Basic objectives2

Pharmacokinetics

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Remimazolam is administered to patients undergoing cardiac surgery and arterial blood draws are performed as appropriate. Blood draws should be performed only during surgery.

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit

90 years-old >=

Gender

Male and Female

Key inclusion criteria

patients undergoing scheduled cardiac surgery under CPB

Key exclusion criteria

BMI >30 kg/m2, BMI <18 kg/m2, pregnant, myasthenia gravis, acute angle closure glaucoma, patients with severe hepatic dysfunction, emergency surgery

Target sample size

10


Research contact person

Name of lead principal investigator

1st name Ami
Middle name
Last name Sugawara

Organization

Asahikawa Medical University

Division name

Department of Anesthesiology and Critical Care Medicine

Zip code

0788510

Address

2-1-1-1, Midorigaoka-higasi, Asahikawa

TEL

0166652111

Email

asugawara@asahikawa-med.ac.jp


Public contact

Name of contact person

1st name Ami
Middle name
Last name Sugawara

Organization

Asahikawa Medical University

Division name

Department of Anesthesiology and Critical Care Medicine

Zip code

0788510

Address

2-1-1-1, Midorigaoka-higasi, Asahikawa

TEL

0166652111

Homepage URL


Email

asugawara@asahikawa-med.ac.jp


Sponsor or person

Institute

Asahikawa Medical University

Institute

Department

Personal name



Funding Source

Organization

Japan Science and Technology Agency

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Asahikawa medical university Ethics Committee

Address

2-1-1-1, Midorigoka-higashi, Asahikawa

Tel

0166652111

Email

rs-kk.g@asajolawa-med.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 03 Month 16 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2022 Year 06 Month 10 Day

Date of IRB

2022 Year 07 Month 14 Day

Anticipated trial start date

2023 Year 03 Month 16 Day

Last follow-up date

2027 Year 12 Month 31 Day

Date of closure to data entry

2027 Year 12 Month 31 Day

Date trial data considered complete


Date analysis concluded



Other

Other related information

Remimazolam is administered and blood levels are measured


Management information

Registered date

2023 Year 03 Month 15 Day

Last modified on

2024 Year 03 Month 15 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000057506


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name